BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015;41:544-563. [PMID: 25619871 DOI: 10.1111/apt.13081] [Cited by in Crossref: 87] [Cited by in F6Publishing: 83] [Article Influence: 12.4] [Reference Citation Analysis]
Number Citing Articles
1 Nuño Solinís R, Arratibel Ugarte P, Rojo A, Sanchez Gonzalez Y. Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. Infect Dis Ther 2016;5:491-508. [PMID: 27783223 DOI: 10.1007/s40121-016-0134-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
2 Fukuda H, Sato D, Moriwaki K, Ishida H. Differences in healthcare expenditure estimates according to statistical approach: A nationwide claims database study on patients with hepatocellular carcinoma. PLoS One 2020;15:e0237316. [PMID: 32790706 DOI: 10.1371/journal.pone.0237316] [Reference Citation Analysis]
3 Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC. The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society? Liver Int 2017;37:662-8. [PMID: 27804195 DOI: 10.1111/liv.13298] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
4 Chhatwal J, Chen Q, Kanwal F. Why We Should Be Willing to Pay for Hepatitis C Treatment. Clin Gastroenterol Hepatol 2015;13:1711-3. [PMID: 26091736 DOI: 10.1016/j.cgh.2015.06.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
5 Younossi ZM, Tanaka A, Eguchi Y, Henry L, Beckerman R, Mizokami M. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan. J Viral Hepat 2018;25:945-51. [DOI: 10.1111/jvh.12886] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
6 Saab S, Jimenez M, Fong T, Wu C, Bau S, Jamal Z, Grotts J, Elashoff D. Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States. J Clin Transl Hepatol 2016;4:76-82. [PMID: 27350937 DOI: 10.14218/JCTH.2016.00011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
7 Younossi ZM, Chan HLY, Dan YY, Lee MH, Lim YS, Kruger E, Tan SC. Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. J Viral Hepat. 2018;25:228-235. [PMID: 29053909 DOI: 10.1111/jvh.12808] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
8 Allen AM, Van Houten HK, Sangaralingham LR, Talwalkar JA, McCoy RG. Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database. Hepatology 2018;68:2230-8. [PMID: 29774589 DOI: 10.1002/hep.30094] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 10.3] [Reference Citation Analysis]
9 Henry L, Younossi Z. Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C. Expert Rev Pharmacoecon Outcomes Res 2016;16:659-65. [PMID: 27710134 DOI: 10.1080/14737167.2016.1244007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
10 Younossi ZM, Tanaka A, Eguchi Y, Lim YS, Yu ML, Kawada N, Dan YY, Brooks-Rooney C, Negro F, Mondelli MU. The impact of hepatitis C virus outside the liver: Evidence from Asia. Liver Int. 2017;37:159-172. [PMID: 27748564 DOI: 10.1111/liv.13272] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
11 Younossi ZM, Stepanova M, Henry L, Nader F, Hunt S. An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens. Am J Gastroenterol. 2016;111:808-816. [PMID: 27021197 DOI: 10.1038/ajg.2016.99] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 12.3] [Reference Citation Analysis]
12 Song J, Han X, Yao Y, Li Y, Zhang J, Shao D, Hou L, Fan Y, Song S, Lian L, Nan J, Wu Y. Acanthoic acid suppresses lipin1/2 via TLR4 and IRAK4 signalling pathways in EtOH- and lipopolysaccharide-induced hepatic lipogenesis. Journal of Pharmacy and Pharmacology 2018;70:393-403. [DOI: 10.1111/jphp.12877] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
13 Fukuda H, Yano Y, Sato D, Ohde S, Noto S, Watanabe R, Takahashi O. Healthcare Expenditures for the Treatment of Patients Infected with Hepatitis C Virus in Japan. Pharmacoeconomics 2020;38:297-306. [PMID: 31761994 DOI: 10.1007/s40273-019-00861-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Cenderello G, Artioli S, Viscoli C, Pasa A, Giacomini M, Giannini B, Dentone C, Nicolini LA, Cassola G, Di Biagio A. Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation. Clinicoecon Outcomes Res 2016;8:15-21. [PMID: 26770065 DOI: 10.2147/CEOR.S93641] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Leidner AJ, Chesson HW, Spradling PR, Holmberg SD. Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease. Appl Health Econ Health Policy 2017;15:65-74. [PMID: 27480538 DOI: 10.1007/s40258-016-0261-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
16 Jayasekera CR, Beckerman R, Smith N, Perumpail RB, Wong RJ, Younossi ZM, Ahmed A. Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States. J Clin Transl Hepatol 2017;5:16-22. [PMID: 28507921 DOI: 10.14218/JCTH.2016.00052] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Gordon S, Lee J, Smith N, Dieterich D. Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States. Expert Rev Pharmacoecon Outcomes Res 2020;20:251-7. [PMID: 31204882 DOI: 10.1080/14737167.2019.1629291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
18 Saab S, Virabhak S, Parisé H, Johnson S, Wang A, Misurski D, Gonzalez YS, Juday T. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States. Adv Ther 2016;33:1316-30. [PMID: 27342742 DOI: 10.1007/s12325-016-0362-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
19 Lo AO, Chan HL, Wong VW, Wong GL. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong. J Gastroenterol Hepatol 2017;32:1071-8. [PMID: 28449343 DOI: 10.1111/jgh.13638] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
20 Chen GF, Wei L, Chen J, Duan ZP, Dou XG, Xie Q, Zhang WH, Lu LG, Fan JG, Cheng J. Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. PLoS One. 2016;11:e0155934. [PMID: 27276081 DOI: 10.1371/journal.pone.0155934] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
21 Greenaway C, Makarenko I, Chakra CNA, Alabdulkarim B, Christensen R, Palayew A, Tran A, Staub L, Pareek M, Meerpohl JJ, Noori T, Veldhuijzen I, Pottie K, Castelli F, Morton RL. The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review. Int J Environ Res Public Health 2018;15:E2013. [PMID: 30223539 DOI: 10.3390/ijerph15092013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
22 Keating GM. Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. Drugs. 2015;75:675-685. [PMID: 25837989 DOI: 10.1007/s40265-015-0381-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 8.3] [Reference Citation Analysis]
23 Younossi Z. What is the ethical responsibility of a provider when prescribing the new direct-acting antiviral agents to patients with hepatitis C infection? Clin Liver Dis (Hoboken) 2015;6:117-9. [PMID: 31041004 DOI: 10.1002/cld.509] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
24 Jena AB, Snider JT, Diaz Espinosa O, Ingram A, Sanchez Gonzalez Y, Lakdawalla D. How Does Treating Chronic Hepatitis C Affect Individuals in Need of Organ Transplants in the United Kingdom? Value Health 2019;22:669-76. [PMID: 31198184 DOI: 10.1016/j.jval.2018.09.2923] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
25 Tapper EB, Afdhal NH, Curry MP. Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C. Transplantation. 2017;101:933-937. [PMID: 28437385 DOI: 10.1097/tp.0000000000001611] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
26 Nguyen JT, Rich JD, Brockmann BW, Vohr F, Spaulding A, Montague BT. A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System. J Urban Health 2015;92:635-49. [PMID: 25828149 DOI: 10.1007/s11524-015-9953-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
27 Younossi ZM, Stepanova M, Asselah T, Foster G, Patel K, Bräu N, Swain M, Tran T, Esteban R, Colombo M, Pianko S, Henry L, Bourliere M. Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. Clin Infect Dis 2018;66:1742-50. [PMID: 29272349 DOI: 10.1093/cid/cix1106] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
28 Jeffrey AW, Huang Y, de Boer WB, Adams LA, MacQuillan G, Speers D, Joseph J, Jeffrey GP. Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcome. World J Hepatol 2017; 9(19): 850-856 [PMID: 28740596 DOI: 10.4254/wjh.v9.i19.850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
29 Vermehren J, Maasoumy B, Maan R, Cloherty G, Berkowski C, Feld JJ, Cornberg M, Pawlotsky JM, Zeuzem S, Manns MP, Sarrazin C, Wedemeyer H. Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. Clin Infect Dis 2016;62:1228-34. [PMID: 26908802 DOI: 10.1093/cid/ciw061] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
30 Fraser I, Burger J, Lubbe M, Dranitsaris G, Sonderup M, Stander T. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa. Pharmacoeconomics 2016;34:403-17. [PMID: 26666639 DOI: 10.1007/s40273-015-0356-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
31 Cacoub P, Buggisch P, Carrión JA, Cooke GS, Zignego AL, Beckerman R, Younossi Z. Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. J Viral Hepat 2018;25:811-7. [DOI: 10.1111/jvh.12881] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
32 Li X, Chan NS, Tam AW, Hung IFN, Chan EW. Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong. Eur J Clin Microbiol Infect Dis. 2017;36:1801-1809. [PMID: 28516201 DOI: 10.1007/s10096-017-2995-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
33 Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC. Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care. Medicine (Baltimore) 2016;95:e5048. [PMID: 27741116 DOI: 10.1097/MD.0000000000005048] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 5.4] [Reference Citation Analysis]
34 Vermehren J, Peiffer K, Welsch C, Grammatikos G, Welker M, Weiler N, Zeuzem S, Welzel TM, Sarrazin C. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2016;44:856-65. [DOI: 10.1111/apt.13769] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 10.2] [Reference Citation Analysis]
35 Saab S, Challita Y, Chen PH, Jimenez MA, Lee AD, Saab EG, Ahn T, Choi G, Durazo FA, El-Kabany MM, Han SB, Grotts J, Agopian VG, Busuttil RW. Elimination of Hepatitis C in Liver Transplant Recipients. J Clin Transl Hepatol 2018;6:247-50. [PMID: 30271735 DOI: 10.14218/JCTH.2017.00079] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
36 Lowe HI, Toyang NJ, McLaughlin W. Potential of Cannabidiol for the Treatment of Viral Hepatitis. Pharmacognosy Res 2017;9:116-8. [PMID: 28250664 DOI: 10.4103/0974-8490.199780] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
37 Clément V, Raimond V. Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs. Value Health 2019;22:220-4. [PMID: 30711067 DOI: 10.1016/j.jval.2018.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Kaplan DE. Cost/Benefit of Hepatitis C Treatment: It Does Not End with SVR. Dig Dis Sci 2018;63:1376-7. [PMID: 29550966 DOI: 10.1007/s10620-018-5014-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Chen H, Chen L. Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China. PLoS One. 2017;12:e0175189. [PMID: 28380022 DOI: 10.1371/journal.pone.0175189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
40 Moon AM, Green PK, Berry K, Ioannou GN. Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. Aliment Pharmacol Ther 2017;45:1201-12. [PMID: 28271521 DOI: 10.1111/apt.14021] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
41 Del Bello D, Cha A, Sorbera M, Bichoupan K, Levine C, Doyle E, Harty A, Patel N, Ng M, Gardenier D. Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV. Clin Infect Dis. 2016;62:1497-1504. [PMID: 26936665 DOI: 10.1093/cid/ciw119] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
42 Aas CF, Vold JH, Skurtveit S, Odsbu I, Chalabianloo F, Økland JM, Leiva RAM, Vickerman P, Johansson KA, Fadnes LT. On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017. BMJ Open 2020;10:e036355. [PMID: 32847908 DOI: 10.1136/bmjopen-2019-036355] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Park H, Wang W, Henry L, Nelson DR. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States. Hepatology 2019;69:1032-45. [PMID: 30289989 DOI: 10.1002/hep.30303] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
44 McElroy HJ, Roberts SK, Thompson AJ, Angus PW, McKenna SJ, Warren E, Musgrave S. Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study. J Med Econ 2017;20:72-81. [PMID: 27552282 DOI: 10.1080/13696998.2016.1227827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
45 Maunoury F, Clément A, Nwankwo C, Levy-Bachelot L, Abergel A, Di Martino V, Thervet E, Durand-Zaleski I. Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France. PLoS One 2018;13:e0194329. [PMID: 29543897 DOI: 10.1371/journal.pone.0194329] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
46 Gadiparthi C, Cholankeril G, Perumpail BJ, Yoo ER, Satapathy SK, Nair S, Ahmed A. Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates. World J Gastroenterol 2018; 24(3): 315-322 [PMID: 29391754 DOI: 10.3748/wjg.v24.i3.315] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
47 Ali S, Ur-Rehman T, Ali M, Haque S, Rasheed F, Lougher E, Nawaz MS, Paudyal V. Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programme. Int J Clin Pharm 2021;43:958-68. [PMID: 33247820 DOI: 10.1007/s11096-020-01202-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Turnes J, Domínguez-hernández R, Casado MÁ. Análisis coste-efectividad de dos estrategias de tratamiento para la hepatitis C crónica: antes y después del acceso a los agentes antivirales de acción directa en España. Gastroenterología y Hepatología 2017;40:433-46. [DOI: 10.1016/j.gastrohep.2017.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
49 Chhatwal J, He T, Lopez-Olivo MA. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals. Pharmacoeconomics 2016;34:551-67. [PMID: 26748919 DOI: 10.1007/s40273-015-0373-9] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 11.8] [Reference Citation Analysis]
50 Castro R, Crathorne L, Perazzo H, Silva J, Cooper C, Varley-Campbell J, Marinho DS, Haasova M, Veloso VG, Anderson R, Hyde C. Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses. BMC Med Res Methodol 2018;18:53. [PMID: 29895281 DOI: 10.1186/s12874-018-0515-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
51 Buti M, Domínguez-Hernández R, Oyagüez I, Casado MA, Esteban R. Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis. J Viral Hepat 2017;24:750-8. [PMID: 28273410 DOI: 10.1111/jvh.12704] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
52 Cheng JC, Tseng CP, Liao MH, Peng CY, Yu JS, Chuang PH, Huang JT, Chen JJW. Activation of hepatic stellate cells by the ubiquitin C-terminal hydrolase 1 protein secreted from hepatitis C virus-infected hepatocytes. Sci Rep 2017;7:4448. [PMID: 28667290 DOI: 10.1038/s41598-017-04259-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
53 Krüger K, Krauth C, Rossol S, Mauss S, Boeker KHW, Müller T, Klinker H, Pathil A, Heyne R, Stahmeyer JT; Collaborators DHC-R. Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry. Eur J Gastroenterol Hepatol 2019;31:230-40. [PMID: 30325794 DOI: 10.1097/MEG.0000000000001283] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
54 Younossi ZM. The price of shortening anti-hepatitis C virus therapy: Is this truly cost saving? Clin Liver Dis (Hoboken) 2015;6:126-8. [PMID: 31041007 DOI: 10.1002/cld.514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
55 Younossi Z, Blissett D, Blissett R, Henry L, Younossi Y, Beckerman R, Hunt S. In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered. Liver Int 2018;38:258-65. [PMID: 28719013 DOI: 10.1111/liv.13519] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
56 Chhatwal J, He T, Hur C, Lopez-Olivo MA. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving. Clin Gastroenterol Hepatol. 2017;15:827-837.e8. [PMID: 27650326 DOI: 10.1016/j.cgh.2016.09.015] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 10.5] [Reference Citation Analysis]
57 Suda KJ, Halbur DJ, Hunkler RJ, Matusiak LM, Schumock GT. Spending on Hepatitis C Antivirals in the United States, 2009-2015. Pharmacotherapy 2017;37:65-70. [DOI: 10.1002/phar.1865] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
58 Faria R, Woods B, Griffin S, Palmer S, Sculpher M, Ryder SD. Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals. Aliment Pharmacol Ther 2016;44:866-76. [DOI: 10.1111/apt.13775] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
59 Igarashi A, Tang W, Guerra I, Marié L, Cure S, Lopresti M. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan. Curr Med Res Opin 2017;33:11-21. [PMID: 27609424 DOI: 10.1080/03007995.2016.1222513] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
60 Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, Racila A, Hunt S, Beckerman R. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577-1586. [PMID: 27543837 DOI: 10.1002/hep.28785] [Cited by in Crossref: 459] [Cited by in F6Publishing: 451] [Article Influence: 76.5] [Reference Citation Analysis]
61 Stepanova M, Younossi ZM. Economic Burden of Hepatitis C Infection. Clin Liver Dis. 2017;21:579-594. [PMID: 28689595 DOI: 10.1016/j.cld.2017.03.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
62 Elbasha EH, Robertson MN, Nwankwo C. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. Aliment Pharmacol Ther 2017;45:455-67. [PMID: 27910116 DOI: 10.1111/apt.13882] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
63 de Bruijn W, Ibáñez C, Frisk P, Bak Pedersen H, Alkan A, Vella Bonanno P, Brkičić LS, Bucsics A, Dedet G, Eriksen J, Fadare JO, Fürst J, Gallego G, Godói IP, Guerra Júnior AA, Gürsöz H, Jan S, Jones J, Joppi R, Kerman S, Laius O, Madzikwa N, Magnússon E, Maticic M, Markovic-Pekovic V, Massele A, Ogunleye O, O'Leary A, Piessnegger J, Sermet C, Simoens S, Tiroyakgosi C, Truter I, Thyberg M, Tomekova K, Wladysiuk M, Vandoros S, Vural EH, Zara C, Godman B. Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Front Pharmacol 2016;7:197. [PMID: 27516740 DOI: 10.3389/fphar.2016.00197] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
64 Buti M, Domínguez-Hernández R, Casado MÁ, Sabater E, Esteban R. Healthcare value of implementing hepatitis C screening in the adult general population in Spain. PLoS One 2018;13:e0208036. [PMID: 30485377 DOI: 10.1371/journal.pone.0208036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
65 Saab S, Parisé H, Virabhak S, Wang A, Marx SE, Sanchez Gonzalez Y, Misurski D, Johnson S. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. J Med Econ 2016;19:795-805. [PMID: 27063573 DOI: 10.1080/13696998.2016.1176030] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
66 Cacoub P, Vautier M, Desbois AC, Saadoun D, Younossi Z. Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France. Aliment Pharmacol Ther. 2018;47:123-128. [PMID: 29044584 DOI: 10.1111/apt.14382] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
67 Stahmeyer JT, Rossol S, Liersch S, Guerra I, Krauth C. Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany. PLoS One 2017;12:e0169401. [PMID: 28046099 DOI: 10.1371/journal.pone.0169401] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
68 Manca F, Robinson E, Dillon JF, Boyd KA. Eradicating hepatitis C: Are novel screening strategies for people who inject drugs cost-effective? Int J Drug Policy 2020;82:102811. [PMID: 32585583 DOI: 10.1016/j.drugpo.2020.102811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Younossi ZM, Stepanova M, Gordon S, Zeuzem S, Mann MP, Jacobson I, Bourliere M, Cooper C, Flamm S, Reddy KR, Kowdley K, Younossi I, Hunt S. Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir. Clin Gastroenterol Hepatol 2018;16:567-574.e6. [PMID: 29155352 DOI: 10.1016/j.cgh.2017.11.023] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
70 Buchanan R, Cooper K, Grellier L, Khakoo SI, Parkes J. The testing of people with any risk factor for hepatitis C in community pharmacies is cost-effective. J Viral Hepat 2020;27:36-44. [PMID: 31520434 DOI: 10.1111/jvh.13207] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
71 Stahmeyer JT, Rossol S, Bert F, Böker KH, Bruch HR, Eisenbach C, Link R, John C, Mauss S, Heyne R, Schott E, Pfeiffer-Vornkahl H, Hüppe D, Krauth C. Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study. PLoS One 2016;11:e0159976. [PMID: 27467772 DOI: 10.1371/journal.pone.0159976] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
72 Curry MP, Tapper EB, Bacon B, Dieterich D, Flamm SL, Guest L, Kowdley KV, Lee Y, Milligan S, Tsai N, Younossi Z, Afdhal NH. Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients. Aliment Pharmacol Ther 2017;46:540-8. [PMID: 28691377 DOI: 10.1111/apt.14204] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
73 Lu NT, Crespi CM, Liu NM, Vu JQ, Ahmadieh Y, Wu S, Lin S, McClune A, Durazo F, Saab S, Han S, Neiman DC, Beaven S, French SW. A Phase I Dose Escalation Study Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in Patients with Chronic Hepatitis C. Phytother Res 2016;30:160-8. [PMID: 26621580 DOI: 10.1002/ptr.5518] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
74 Allison RD, Hale SA, Harvey BJ, Hudson TL, Livingston CJ, Sherin KM, Uduhiri KA, Niebuhr DW. The American College of Preventive Medicine Position Statement on Hepatitis C Virus Infection. American Journal of Preventive Medicine 2016;50:419-26. [DOI: 10.1016/j.amepre.2015.12.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
75 Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology 2016;150:1599-608. [DOI: 10.1053/j.gastro.2016.02.039] [Cited by in Crossref: 204] [Cited by in F6Publishing: 183] [Article Influence: 34.0] [Reference Citation Analysis]
76 Puig-Junoy J, Pascual-Argente N, Puig-Codina L, Planellas L, Solozabal M. Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review. Expert Rev Gastroenterol Hepatol 2018;12:1251-63. [PMID: 30791790 DOI: 10.1080/17474124.2018.1540929] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
77 Kim DY, Wong G, Lee J, Kim MH, Smith N, Blissett R, Kim HJ. Cost-effectiveness of increased screening and treatment of chronic hepatitis C in Korea. Curr Med Res Opin 2020;36:993-1002. [PMID: 32295431 DOI: 10.1080/03007995.2020.1756232] [Reference Citation Analysis]
78 Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. Aliment Pharmacol Ther 2016;44:1090-101. [PMID: 27640785 DOI: 10.1111/apt.13798] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
79 Alavian SM, Nikfar S, Kebriaeezadeh A, Lotfi F, Sanati E, Rezaei Hemami M, Keshavarz K. A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. Iran Red Crescent Med J 2016;18:e37094. [PMID: 28203449 DOI: 10.5812/ircmj.37094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
80 Tsai PC, Liu TW, Hsieh MH, Yeh ML, Liang PC, Lin YH, Huang CI, Huang CF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML. A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naïve chronic hepatitis C patients in Taiwan. Kaohsiung J Med Sci 2017;33:44-9. [PMID: 28088273 DOI: 10.1016/j.kjms.2016.10.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
81 Yang H, Huang Y, Wu D, Yan J, He J, Li H. In vitro investigation of the interaction between the hepatitis C virus drug sofosbuvir and human serum albumin through 1 H NMR, molecular docking, and spectroscopic analyses. New J Chem 2016;40:2530-40. [DOI: 10.1039/c5nj02003d] [Cited by in Crossref: 28] [Article Influence: 4.7] [Reference Citation Analysis]
82 Bickerstaff C. The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C. Expert Rev Pharmacoecon Outcomes Res 2015;15:787-800. [PMID: 26289734 DOI: 10.1586/14737167.2015.1076337] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
83 Younossi ZM, Birerdinc A, Henry L. Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences. Journal of Hepatology 2016;65:S109-19. [DOI: 10.1016/j.jhep.2016.07.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 7.2] [Reference Citation Analysis]
84 Lynch SM, Wu GY. Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy. J Clin Transl Hepatol 2016;4:310-9. [PMID: 28097100 DOI: 10.14218/JCTH.2016.00027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 18] [Article Influence: 0.3] [Reference Citation Analysis]